Skip to Content

Join the 'Prolia' group to help and get support from people like you.

Prolia News

FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis

Posted 29 May 2018 by Drugs.com

THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed ...

Breast Cancer Drugs Battle Disease's Return

Posted 9 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 9, 2015 – A pair of drugs already on the market appear to reduce the recurrence of breast cancer in women who've already undergone treatment, two new clinical trials show. The chemotherapy drug capecitabine (Afinitor) seems to reduce by nearly a third the risk of breast cancer recurrence if women receive the drug following surgery to remove their cancer, researchers were to ...

Strong Bones After 50? Women May Not Need Next Test Until 65

Posted 9 Jun 2015 by Drugs.com

TUESDAY, June 9, 2015 – A postmenopausal woman who is 50 and still shows "normal" readings on her bone density test may not need her next such test for 10 or even 15 years, a new study finds. However, researchers led by Dr. Margaret Gourlay of the University of North Carolina at Chapel Hill stressed that younger women who do show signs of bone loss are at high risk for a major fracture, and do ...

Osteoporosis Drugs Work, But Review Finds No Clear Winner

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Many osteoporosis drugs cut women's risk of suffering a bone fracture, though it's not clear whether any one medication works better than others, a new research review finds. Reporting Sept. 8 in Annals of Internal Medicine, researchers said that for women with the bone-thinning disease osteoporosis, various drugs cut the risk of a spine fracture by 40 to 60 percent, ...

FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy

Posted 19 Sep 2011 by Drugs.com

THOUSAND OAKS, Calif., September 19, 2011, 2011 /PRNewswire/ – Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture ...

Ask a Question

Further Information

Related Condition Support Groups

Osteoporosis

Prolia Patient Information at Drugs.com